StockData
Inhibitor Therapeutics, Inc. logo

Inhibitor Therapeutics, Inc. (INTI) stock

INTIOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.11+0.00 (+0.09%)

Close on Oct 19, 2026Market cap $19.06MP/E –Yield –

Inhibitor Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Inhibitor Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$3.22M. For fiscal 2025 it was -$3.23M. The highest annual figure on record is $11.74M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.23M–
FY2024Dec 31, 2024-$3.23M–
FY2023Dec 31, 2023-$2.70M-123.0%
FY2022Dec 31, 2022$11.74M–
FY2021Dec 31, 2021-$220.43K–
FY2020Dec 31, 2020-$825.36K–
FY2019Dec 31, 2019-$2.71M–
FY2018Dec 31, 2018-$3.71M–
FY2017Dec 31, 2017-$2.91M–
FY2016Dec 31, 2016-$3.76M–
FY2015Dec 31, 2015-$2.26M–
FY2014Dec 31, 2014-$1.30M–
FY2013Dec 31, 2013-$1.22M–
FY2012Dec 31, 2012-$464.27K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$775.22K–
Q1 FY2026Mar 31, 2026-$1.08M–
Q4 FY2025Dec 31, 2025-$601.17K–
Q3 FY2025Sep 30, 2025-$761.25K–
Q2 FY2025Jun 30, 2025-$583.99K–
Q1 FY2025Mar 31, 2025-$1.28M–
Q4 FY2024Dec 31, 2024-$771.44K–
Q3 FY2024Sep 30, 2024-$720.44K–
Q2 FY2024Jun 30, 2024-$583.08K–
Q1 FY2024Mar 31, 2024-$1.16M–
Q4 FY2023Dec 31, 2023-$697.71K-105.9%
Q3 FY2023Sep 30, 2023-$562.71K–
Q2 FY2023Jun 30, 2023-$682.61K–
Q1 FY2023Mar 31, 2023-$757.28K–
Q4 FY2022Dec 31, 2022$11.90M–
Q3 FY2022Sep 30, 2022-$51.89K–
Q2 FY2022Jun 30, 2022-$61.49K–
Q1 FY2022Mar 31, 2022-$44.19K–
Q4 FY2021Dec 31, 2021-$22.66K–
Q3 FY2021Sep 30, 2021-$40.43K–
Q2 FY2021Jun 30, 2021-$65.47K–
Q1 FY2021Mar 31, 2021-$91.87K–
Q4 FY2020Dec 31, 2020-$16.65K–
Q3 FY2020Sep 30, 2020-$100.61K–
Q2 FY2020Jun 30, 2020-$206.97K–
Q1 FY2020Mar 31, 2020-$501.13K–
Q4 FY2019Dec 31, 2019-$568.37K–
Q3 FY2019Sep 30, 2019-$553.84K–
Q2 FY2019Jun 30, 2019-$605.52K–
Q1 FY2019Mar 31, 2019-$977.99K–
Q4 FY2018Dec 31, 2018-$832.11K–
Q3 FY2018Sep 30, 2018-$954.93K–
Q2 FY2018Jun 30, 2018-$789.54K–
Q1 FY2018Mar 31, 2018-$1.13M–
Q4 FY2017Dec 31, 2017-$543.25K–
Q3 FY2017Sep 30, 2017-$756.05K–
Q2 FY2017Jun 30, 2017-$745.91K–
Q1 FY2017Mar 31, 2017-$867.88K–
Q4 FY2016Dec 31, 2016-$1.21M–
Q3 FY2016Sep 30, 2016-$1.06M–

More Inhibitor Therapeutics figures

See a number that looks wrong?